Capvaxive
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Pneumococcal polysaccharide conjugate vaccine (21-valent)
- Made by
- Merck Sharp & Dohme B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in children and adolescents 2 to less than 18 years of age who previously completed a primary paediatric pneumococcal vaccination regimen. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. The use of Capvaxive should be in accordance with official recommendations.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Merck Sharp & Dohme B.V. |
|---|---|
| Active substance | Pneumococcal polysaccharide conjugate vaccine (21-valent) |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J07AL02 · Antibiotics, antivirals and antifungals taken into the body |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-03-24 |
| Last updated by the regulator | 2026-06-01 |
| EMA product number | EMEA/H/C/006267 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).